参芪扶正注射液在晚期非小细胞肺癌患者治疗中的效果  

Efficacy of Shenqi Fuzheng Injection in the Treatment of Advanced Non-small Cell Lung Cancer Patients

作　　者：雷小平 孙雅菊 LEI Xiaoping;SUN Yaju(Hospital of People′s Liberation Army Logistics Support Unit,Shaanxi Baoji 721000,China)

机构地区：[1]中国人民解放军联勤保障部队第九八七医院,陕西宝鸡721000

出　　处：《中国医药导刊》2023年第4期425-429,共5页Chinese Journal of Medicinal Guide

摘　　要：目的:探究基于实验室检查指标、肺癌生存质量评价(FACT-L)量表评价参芪扶正注射液治疗晚期非小细胞肺癌(NSCLC)的效果。方法:选取我院2020年3月至2022年3月收治的晚期NSCLC患者108例,按照随机数字表法分为对照组与观察组,每组各54例,对照组给予长春瑞滨、顺铂化疗,观察组在对照组治疗的基础上加用参芪扶正注射液,两组患者持续干预1个疗程,其中1个化疗周期为20 d,2个化疗周期为1个疗程,共40 d,比较治疗1个疗程后两组患者治疗临床疗效、外周血Th17/Treg比例、不良反应发生率及FACT-L评分。结果:治疗1个疗程后,对照组的治疗总有效率高于观察组(P<0.05);治疗1个疗程后,两组患者外周血Th17、Th17/Treg值均高于治疗前,Treg值均低于治疗前,且观察组患者外周血Th17、Th17/Treg值增幅、Treg值减幅均优于对照组(P<0.05)。治疗1个疗程后,观察组患者不良反应发生率低于对照组(P<0.05);治疗1个疗程后,两组患者FACT-L评分均高于治疗前,且观察组患者FACT-L评分高于对照组(P<0.05)。结论:对于晚期NSCLC患者,在长春瑞滨、顺铂化疗的基础上加用参芪扶正注射液,患者临床疗效较好,可改善患者外周血Th17、Treg、Th17/Treg值,并可降低不良反应发生率,进而改善患者生存质量。Objective:To explore the efficacy of shenqi fuzheng injection in the treatment of advanced non-small cell lung cancer(NSCLC)patients based on laboratory test indicators and FACT-L scale.Methods:A total of 108 patients with advanced NSCLC admitted in our hospital from March 2020 to March 2022 were randomly divided into the control group and the observation group,with 54 cases in each group.The control group was given vinorelbine and cisplatin chemotherapy,and the observation group was given shenqi fuzheng injection on the basis of the control group.The treatment lasted for 1 course in both groups.The duration of one chemotherapy cycle was 20 d,and the duration of two chemotherapy cycles was 1 course,a total of 40 d.The clinical efficacy,Th17/Treg ratio in peripheral blood,incidence of toxicity and side effects and FACT-L score of of the two groups of patientsafter one course of treatment.Results:After one course of treatment,the clinical efficacy of the observation group was better than that of the control group(P<0.05).After one course of treatment,The levels of Th17 and TH17/Treg in peripheral blood were higher and the levels of Treg were lower in both groups than those before treatment.The increase of Th17,Th17/Treg and the decrease of Treg in the observation group were better than those of the control group(P<0.05).After one course of treatment,the incidence of toxicity and side effects in the observation group was lower than that of the control group(P<0.05).After one course of treatment,the FACT-L score of both groups was higher than that before treatment,and compared with the FACT-L score of the control group,the FACT-L score of the observation group was higher(P<0.05).Conclusion:Shenqi fuzheng injection combined with vinorelbine and cisplatin has good clinical efficacy in patients with advanced NSCLC,which can improve the Th17,Treg,Th17/Treg ratio in peripheral blood of patients and reduce the incidence of toxic and side effects,so as to improve the quality of life of patients.

关 键 词：晚期非小细胞肺癌 血清相关肿瘤标志物 不良反应发生率 生存质量 

分 类 号：R734.2[医药卫生—肿瘤]